Nephrology & Renal Supplements

Torsemide / Torasemide Tablets (5mg, 40mg) is a long-acting pyridine-sulfonylurea loop diuretic on the WHO Model List framework. It inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of Henle's loop, blocking active sodium and chloride reabsorption. It features high oral bioavailability (~80%), consistent absorption regardless of intestinal mucosal edema, and an extended duration of action (~12 hours) with anti-aldosteronergic properties that cause less potassium wasting than furosemide. Indicated for treatment of edema associated with congestive heart failure, chronic kidney disease (CKD), nephrotic syndrome, hepatic cirrhosis, and management of hypertension.

Torsemide / Torasemide Tablets (5mg, 40mg) is a long-acting pyridine-sulfonylurea loop diuretic on the WHO Model List framework. It inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of Henle's loop, blocking active sodium and chloride reabsorption. It features high oral bioavailability (~80%), consistent absorption regardless of intestinal mucosal edema, and an extended duration of action (~12 hours) with anti-aldosteronergic properties that cause less potassium wasting than furosemide. Indicated for treatment of edema associated with congestive heart failure, chronic kidney disease (CKD), nephrotic syndrome, hepatic cirrhosis, and management of hypertension.

Potassium Citrate (1100mg) and Magnesium Citrate (375mg, with or without Pyridoxine 20mg or Citric Acid 334mg per 5ml) Oral Solution is a specialized dual-mineral nephrolithiasis inhibitor on the PMBI formulary. Absorbed citrate is metabolized to bicarbonate, alkalinizing the urine and increasing urinary citrate excretion. Citrate forms soluble chelates with calcium, preventing calcium oxalate and calcium phosphate crystal nucleation and agglomeration. Magnesium competes with calcium to form highly soluble magnesium oxalate, further retarding stone growth. Pyridoxine (vitamin B6) acts as a cofactor for alanine:glyoxylate aminotransferase, reducing endogenous oxalate production. Indicated for renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis.

N-Acetylcysteine (150mg) and Taurine (500mg) Tablets is a fixed-dose nephroprotective and antioxidant combination on the PMBI formulary. N-Acetylcysteine (NAC) is a glutathione precursor that replenishes intracellular cysteine pools, scavenges reactive oxygen species (ROS), improves renal hemodynamics, and downregulates pro-fibrotic TGF-beta signaling. Taurine (2-aminoethanesulfonic acid) is an abundant intracellular sulfur amino acid that modulates osmoregulation, maintains mitochondrial electron transport, inhibits renal tubular cell apoptosis, and prevents advanced glycation end-product (AGE) accumulation. Indicated for adjunctive renal protection in diabetic nephropathy, early-stage chronic kidney disease (CKD), and prevention of contrast-induced nephropathy.

Potassium Citrate (1100mg) and Magnesium Citrate (375mg, with or without Pyridoxine 20mg or Citric Acid 334mg per 5ml) Oral Solution is a specialized dual-mineral nephrolithiasis inhibitor on the PMBI formulary. Absorbed citrate is metabolized to bicarbonate, alkalinizing the urine and increasing urinary citrate excretion. Citrate forms soluble chelates with calcium, preventing calcium oxalate and calcium phosphate crystal nucleation and agglomeration. Magnesium competes with calcium to form highly soluble magnesium oxalate, further retarding stone growth. Pyridoxine (vitamin B6) acts as a cofactor for alanine:glyoxylate aminotransferase, reducing endogenous oxalate production. Indicated for renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis.

Sevelamer Carbonate / Hydrochloride Tablets (400mg, 800mg) is a non-calcium, non-aluminum, non-absorbable cross-linked polymeric phosphate binder on the WHO Model List framework. In the gastrointestinal tract, its multiple amine groups become partially protonated at physiological intestinal pH, binding dietary phosphate through ionic and hydrogen bonding. The bound phosphate is excreted in the feces, decreasing intestinal phosphate absorption without releasing calcium or aluminum into the bloodstream. This prevents hypercalcemia, calciphylaxis, and metastatic vascular calcification. Indicated for the control of hyperphosphatemia in adult and pediatric patients with Chronic Kidney Disease (CKD) on hemodialysis or peritoneal dialysis, or non-dialysis CKD with serum phosphorus >= 5.5 mg/dL.

Sevelamer Carbonate / Hydrochloride Tablets (400mg, 800mg) is a non-calcium, non-aluminum, non-absorbable cross-linked polymeric phosphate binder on the WHO Model List framework. In the gastrointestinal tract, its multiple amine groups become partially protonated at physiological intestinal pH, binding dietary phosphate through ionic and hydrogen bonding. The bound phosphate is excreted in the feces, decreasing intestinal phosphate absorption without releasing calcium or aluminum into the bloodstream. This prevents hypercalcemia, calciphylaxis, and metastatic vascular calcification. Indicated for the control of hyperphosphatemia in adult and pediatric patients with Chronic Kidney Disease (CKD) on hemodialysis or peritoneal dialysis, or non-dialysis CKD with serum phosphorus >= 5.5 mg/dL.

Torasemide (10mg) and Spironolactone (25mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination on the WHO Model List framework. Torasemide inhibits the Na+/K+/2Cl- symporter in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Spironolactone competitively antagonizes the mineralocorticoid aldosterone receptor in the distal convoluted tubule and collecting duct, promoting sodium and water excretion while conserving potassium and magnesium ions. Indicated for refractory edema and ascites associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome.

Combi Kit of Torasemide (20mg) Tablets and Eplerenone (25mg) Tablets combines a long-acting loop diuretic with a selective mineralocorticoid receptor antagonist (MRA). Torasemide delivers potent, predictable loop diuresis with minimal urinary potassium wasting compared to furosemide. Eplerenone selectively blocks aldosterone without binding to androgen or progesterone receptors, completely eliminating gynecomastia and sexual side effects while preventing hypokalemia. Indicated for severe edema, chronic heart failure with reduced ejection fraction (HFrEF), and refractory hypertension.

Frusemide (40mg) and Amiloride (5mg) Tablets is a balanced loop and potassium-retaining diuretic combination on the WHO Model List of Essential Medicines. Frusemide exerts potent, rapid natriuresis in the loop of Henle, while amiloride blocks luminal epithelial sodium channels (ENaC) in the cortical collecting tubule, blunting potassium excretion without antiandrogenic hormonal effects. Indicated for congestive heart failure edema, hepatic cirrhosis with ascites, and nephrotic edema in patients prone to hypokalemia.

Frusemide (40mg) and Potassium Chloride Controlled Release (600mg CR) Tablets combines a high-ceiling loop diuretic with a potassium replenishment core. Frusemide induces significant renal loss of potassium and chloride alongside sodium and water; the controlled-release potassium chloride wax-matrix core dissolves gradually along the small intestine, replenishing potassium losses and preventing diuretic-induced hypokalemic metabolic alkalosis, muscle weakness, and cardiac dysrhythmias. Indicated for fluid overload in heart failure, nephrotic syndrome, and hepatic edema.

Torasemide (10mg) and Amiloride (5mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination. Torasemide blocks the Na+/K+/2Cl- cotransporter in the loop of Henle, while amiloride selectively blocks epithelial sodium channels (ENaC) in the late distal tubule and cortical collecting duct, preventing potassium loss driven by torasemide's high distal tubular sodium delivery. Indicated for refractory edema associated with congestive heart failure, nephrotic syndrome, and hepatic cirrhosis.

Pyridoxine Hydrochloride Tablets (50mg, 100mg, 100mg Sustained Release) is an oral Vitamin B6 formulation on the WHO Model List of Essential Medicines. Converted to pyridoxal-5-phosphate (PLP), an essential cofactor for over 140 enzymatic reactions including synthesis of neurotransmitters (GABA, serotonin, dopamine) and heme synthesis. Indicated for prevention and treatment of drug-induced peripheral neuropathy (from isoniazid, cycloserine, penicillamine), pyridoxine-dependent seizures in infants, idiopathic morning sickness, and sideroblastic anemia.

Vasopressin Injection (20 IU/ml) is a sterile parenteral formulation of endogenous nonapeptide hormone (antidiuretic hormone / ADH) on the WHO Model List of Essential Medicines. It stimulates vascular V1a receptors on vascular smooth muscle to produce intense systemic vasoconstriction and renal V2 receptors to conserve water. Indicated for vasodilatory shock (septic shock, post-cardiotomy shock) refractory to high-dose norepinephrine, acute bleeding esophageal varices in portal hypertension, and management of severe central diabetes insipidus.